spacer
home > ict > winter 2020 > comparator sourcing in clinical studies (part one of two)
PUBLICATIONS
International Clinical Trials

Comparator Sourcing in Clinical Studies (Part One of Two)




Choosing the right comparator supplier is becoming increasingly important to sponsor companies conducting clinical trials; drug development companies are constantly having to jump through narrower hoops, held higher each year by regulators. Costs to maintain drug integrity throughout the supply chain have risen exponentially over the last decade, and R&D budgets are being slashed like sacrificial lambs in homage to the great God: shareholder value. Mergers and acquisitions, and their resulting layoffs, combined with an ever-increasing number of eager, educated young professionals entering the life science employment sector has created a culture of fear in existing pharmaceutical employees who know that theirs is most definitely not a ‘job for life’. Clinical teams are under constant pressure to execute trials faster, compliantly, more effectively, with greater efficiency and transparency, with minimal risk, and for less money. Oh, and did I mention they have to plan everything at least 18 months in advance, be ready to adapt to any disaster on the turn of a dime, navigate an ever-changing regulatory landscape, but plan and manage any change before it happens? Trust me when I tell you that Ethan Hunt had it easy compared to the trials and tribulations of the average clinical trial supply chain manager. I am sure that countless numbers of these unsung heroes and heroines dream of one day running off to the circus to engage in the slightly less challenging career of juggling chainsaws. Pharma has evolved into a fast-changing environment that has typically feared change of all kinds, regardless of how much money it pumps into change management training for its people. The problem we are facing is that clinical supply chains and comparator drug distribution channels are changing dramatically and, therefore, so must our sourcing models to ensure that study drugs are accessible to patients enrolling in modern day clinical trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Toby Watkins is the Founder and Managing Director of a Swiss-based clinical trial supplies consultancy firm, CTSS, that helps sponsors identify, validate, and manage vendor companies across the clinical trial supply value chain. Over the last decade, Toby has worked on global comparator sourcing programmes helping sponsors source comparator drugs, ancillaries, and reference products and identify their vendors in over 30 countries around the globe. Prior to entering the clinical arena, he worked on named-patient and managed access programmes in emerging markets. Toby has had the privilege of working with many of the world’s innovators, comparator sourcing companies, CROs, CMOs, biotechs, Big Pharma companies, and their suppliers at every stage of drug development across multiple indications.
toby.watkins@clinicaltrialsupplysolutions.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

03rd November, 2021, Rockville, Maryland (USA): Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

Aigenpulse

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement